Somatrogon (growth disturbance due to insufficient secretion of growth hormone; patients aged ≥ 3 - < 18 years)

Subject:

• Active Substance: Somatrogon
• Name: Ngenla^®
• Therapeutic area: Hormonal growth disturbance
• Pharmaceutical company: Pfizer Pharma GmbH

Time table:

• Start: 01.04.2022
• Final decision by G-BA: 15.09.2022

Final decision:

• Hint for a non-quantifiable additional benefit